A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

The following is a summary of “Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for ...

CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...

There are various factors that may potentially increase the risk of developing AMD, such as advancing age (over 50); having a ...

Dr Arshad Khanani anticipates presentations offering new strategies to tackle challenges such as macular atrophy and fibrosis, and optimizing dosing intervals in wet AMD.

This NMA bridges the gap between trials for both therapies and compare them to one another based on existing data.

Age-related macular degeneration is the most common cause ... Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD [MARINA] and Anti-VEGF Antibody for the Treatment ...

Data about higher doses that are injected less often come as the original 2-milligram dose of Eylea is facing an increasing ...

Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety ...

CENTRAL TRUST Co lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.7% in ...

Age-related macular degeneration (AMD) is one of the leading causes of ... There are two main types: dry (atrophic) AMD and wet (neovascular) AMD. Dry AMD is more common, accounting for about 80–90% ...